作者: Eva Szabo
关键词:
摘要: Early phase clinical trials are an essential component of chemopreventive drug development to identify signals efficacy that can subsequently be explored definitively in III trials. Whereas I focus on safety and identification optimal dose schedule for cancer prevention, II intermediate endpoints variably related development. The United States National Cancer Institute supports a programme devoted early prevention experience, along with the benefits limitations range biomarker used these studies, reviewed here.